Strategie di prevenzione e cura in oncologia: differenze di genere

Journal title SALUTE E SOCIETÀ
Author/s Andrea Fontana, Eleonora Bona, Alfredo Falcone
Publishing Year 2014 Issue 2014/1 Language Italian
Pages 14 P. 75-88 File size 526 KB
DOI 10.3280/SES2014-001007
DOI is like a bar code for intellectual property: to have more infomation click here

Below, you can see the article first page

If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits

Article preview

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

Gender difference in cancer susceptibility, incidence, prognosis and aggressiveness have been observed for several types of tumors. Environmental and occupational exposures along with hormonal and immunological differences may be responsible for the disparity between males and females. Tumor immune surveillance, a recognized major physiological mechanism against cancer development and progression, is largely sex-dependent with a great activity in females respect to males. However, up today, no clinical trial evaluating new drugs or treatment strategy have been performed in a gender-specific manner and our knowledge derived from subgroup analysis, especially for what concerns women population. In this review, the authors point out gender differences in cancer epidemiology, response to treatments, toxicity and tumors related side effects. Colorectal and lung cancers will also described in order to underline the main gender differences.

Keywords: Gender Medicine, Cancer Susceptibility, Sex Hormones, Immune Surveillance, Colorectal cancer, Lung Cancer

  1. Aiello M., Vella N., Cannavò C., Scalisi A., Spandidos D.A., Toffoli G., Buonadonna A., Libra M., Stivala F. (2011). Role of genetic polymorphisms and mutations in colorectal cancer therapy. Mol Med Report, 4: 203-208, DOI: 10.3892/mmr.2010.40
  2. Alexandrie A.K., Sundberg M.I., Seidegård J., Tornling G., Rannug A. (1994). Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis, 15(9): 1785-1790, DOI: 10.1093/carcin/15.9.178
  3. Baggio G., Corsini A., Floreani A., Giannini S., Zagonel V. (2013). Gender Medicine: a task for the third millennium. Clin Chem Lab Med, 51(4): 713-727, DOI: 10.1515/cclm-2012-084
  4. Bain C., Feskanich D., Speizer F.E., Thun M., Hertzmark E., Rosner B.A., Colditz G.A. (2004). Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst, 96: 826-834, DOI: 10.1093/jnci/djh14
  5. Cecchin E., D’Andrea M., Lonardi S., Zanusso C., Pella N., Errante D., De Mattia E., Polesel J., Innocenti F., Toffoli G. (2012). A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX regimen). Pharmacogen J, 7 August [Epub ahead of print], DOI: 10.1038/tpj.2012.3
  6. Cheng Y.W., Hsieh L.L., Lin P.P., Chen C.P., Chen C.Y., Lin T.S., Su J.M., Lee H. (2001). Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ Mol Mutagen, 37(4): 304-310, DOI: 10.1164/rccm.200611-1655P
  7. Clark K., Smith J., Lovell M., Currow D.C. (2012). Longitudinal pain reports in a palliative care population. J Palliate Med, 15: 1335-1341, DOI: 10.1089/jpm.2012.029
  8. Chochinov H.M., Tataryn D.J., Wilson K.G. et al. (2000). Prognostic awareness and the terminally ill. Psychosomatics, 41(6): 500-04
  9. (2000). Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg, 119: 21-26, DOI: 10.1016/S0022-5223(00)70213-
  10. Deenen M.J., Cats A., Beijnen J.H., Schellens J.H. (2011). Pharmacogenetic variability in phase II anticancer drug metabolism. Oncologist, 16: 992-1005, DOI: 10.1634/theoncologist.2010-026
  11. Dorak M,T., Karpuzoglu E. (2012). Gender differences in cancer susceptibility: an inadeguately addressed issue. Front Genet, 3: 268-273, DOI: 10.3389/fgene.2012.0026
  12. Edgren G., Liang L., Adami H.O., Cheang E.T. (2012). Enigmatic sex disparities in cancer incidence. Eur J Epidemiol, 27: 187-196, DOI: 10.1007/s10654-011-9647-
  13. Fasco M.J., Hurteau G.J., Spivack S.D. (2002). Gender-dependent expression of alpha and beta estrogen receptors in human non tumor and tumor lung tissue. Mol Cell Endocrinol, 188(1-2): 125-140, DOI: 10.1016/S0303-7207(01)00750-
  14. Fu J.B., Kau T.Y., Severson R.K., Kalemkerian G.P. (2005). Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest, 127: 768-777, DOI: 10.2147/CLEP.S1719
  15. Healy B. (1991). The Yentl syndrome. N Engl J Med, 325: 274-276, DOI: 10.1056/NEJM19910725325040
  16. Helft P.R., Hlubocky F., Wen M. et al. (2003). Associations among awareness of prognosis, hopefulness, and coping in patients with advanced cancer participating in phase I clinical trials. Support Care Cancer, 11(10): 644-51
  17. Iconomou G., Viha A., Koutra A. et al. (2002). Information needs and awareness of diagnosis in patients with cancer receiving chemotherapy: a report from Greece. Palliat Med, 16(4): 315-21) Dec; 25(4): 313-17
  18. Joosse A., Collette S., Suciu S., Nijsten T., Lejeune F., Kleeberg U.R., Coebergh J.W., Eggermont A.M., de Vries E. (2012). Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European organizations for research and treatment of cancer phase III trials. J Clin Oncol, 30: 2240-2247, DOI: 10.1200/JCO.2011.38.058
  19. Kiyohara C., Ohno Y. (2010). Sex difference in lung cancer susceptibility: a review. Gend Med, 7: 381-401, DOI: 10.1016/j.genm.2010.10.00
  20. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J. Jr, Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., Albain K.S., Cella D., Wolf M.K., Averbuch S.D., Ochs J.J., Kay A.C. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290: 2149-2158, DOI: 10.1001/jama.290.16.214
  21. Lin C.C. (1999). Disclosure of the cancer diagnosis as it relates to the quality of pain management among patients with cancer pain in Taiwa. J Pain Symptom Manage, 18: 331-37
  22. Lipshultz S.E., Lipsitz S.R., Mone S.M., Goorin A.M., Sallan S.E., Sanders S.P., Orav E.J., Gelber R.D., Colan S.D. (1995). Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med, 332: 1738-1743, DOI: 10.1056/NEJM19950629332260
  23. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350: 2129-2139, DOI: 10.1056/NEJMoa04093
  24. Mittelstrass K., Ried J.S., Yu Z., Krumsiek J., Gieger C., Prehn C., Roemisch- Margl W., Polonikov A., Peters A., Theis F.J., Meitinger T., Kronenberg F.,Weidinger S., Wichmann H.E., Suhre K., Wang-Sattler R., Adamski J., Illig T. (2011). Discovery of sexual dimorphism in metabolic and genetic biomarkers. PloS Genet, 7, e10022115, DOI: 10.1371/journal.pgen.1002211
  25. Montrone V. et al. (2004). Proposta di una scala di valutazione dello stato di consapevolezza della propria malattia per i pazienti neoplastici: Mo.Lo.Ru. It J Pain Manage e Palliat Care, 2(3): 6-15
  26. Nakamura H., Ando K., Shinmyo T., Morita K., Mochizuki A., Kurimoto N., Tatsunami S. (2011). Female gender is an independent prognostic factors in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg, 17: 469-480, DOI: 10.5761/atcs.oa.10.0163
  27. Nelson H.H., Christiani D.C., Mark E.J., Wiencke J.K., Wain J.C., Kelsey K.T. (1999). Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Ins., 91(23): 2032-2038, DOI: 10.1093/jnci/91.23.203
  28. Nord C., Mykletun A., Fossa S.D. (2003). Cancer patients’ awareness about their diagnosis: a population-based study. J Public Health Med, Dec, 25(4): 313-17
  29. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304: 1497-500, DOI: 10.1126/science.109931
  30. Pal S.K., Hurria A. (2010). Impact of age, sex and comorbidity on cancer therapy and disease progression. J Clin Oncol, 28: 4086-4093, DOI: 10.1200/JCO.2009.27.057
  31. Pronzato P., Bertelli G., Losardo P. et al. (1994). What do advanced cancer patients know of their disease? A report from Italy. Support Care Cancer, Jul, 2(4): 242-44
  32. Radzikowska E., Glaz P., Roszkowski K. (2001). Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol, 13: 1087-1093, DOI: 10.1093/annonc/mdf18
  33. Raso M.G., Behrens C., Herynk M.H., Liu S., Prudkin L., Ozburn N.C., Woods D.M., Tang X., Mehran R.J., Moran C., Lee J.J., Wistuba I.I. (2009). Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res, 15: 5359-5368, DOI: 10.1158/1078-0432.CCR-09-003
  34. Schabath M.B., Spitz M.R., Hong W.K., Delclos G.L., Reynolds W.F., Gunn G.B., Whitehead L.W., Wu X. (2002). A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer, 37(1): 35-40, DOI: 10.1016/S0169-5002(02)00034-
  35. Siegel R., Naishadham D., Jemal A. (2013). Cancer Statistics, 2013. Ca Cancer J Clin, 63: 11-30, DOI: 10.3322/caac.2116
  36. Shriver S.P., Bourdeau H.A., Gubish C.T., Tirpak D.L., Davis A.L.G., Luketich J.D., Siegfried J.M. (2000). Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst, 92(1): 24-33, DOI: 10.1093/jnci/92.1.2
  37. Siegfried J.M. (2001). Women and lung cancer: does oestrogen play a role? Lancet Oncol, 2(8): 506-513, DOI: 10.1016/S1470-2045(01)00457-
  38. Strimpakos A.S., Syrigos K.N., Saif M.V. (2009). Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J, 9: 147-160, DOI: 10.1038/tpj.2009.
  39. Toyooka S., Tsuda T., Gazdar A.F. (2003). The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat, 21: 229-239
  40. Yang D., Hendifar A., Lenz C., Togawa K., Lenz F., Lurje G., Pohl A., Winder T., Ning Y., Groshen S., Lenz H.J. (2011). Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J Gastrointestinal Oncol, 2: 77-84, DOI: 10.3978/j.issn.2078-6891.2010.02
  41. Wong E., Bedard G., Pulenzas N., Lechner B., Lam H., Thavarajah N., Holden L., Chow E., Lauzon N. (2013). Gender differences in symptoms experienced by advanced cancer patients: a literature review. Review in health care, 4: 141-153, DOI: 10.7175/rhc.48342141-15
  42. de Perrot M., Licker M., Bouchardy C., Usel M., Robert J., Spiliopoulos A.

Andrea Fontana, Eleonora Bona, Alfredo Falcone, Strategie di prevenzione e cura in oncologia: differenze di genere in "SALUTE E SOCIETÀ" 1/2014, pp 75-88, DOI: 10.3280/SES2014-001007